Studying the origins of childhood acute myeloid leukaemia to identify targets for kinder and more effective treatments
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
Detecting lingering brain cancer cells before a tumour grows back
Ependymoma comes back after treatment around half of the time, because some cancer cells are still alive. If doctors could identify these cells and diagnose relapsed ependymoma sooner, children could start treatment earlier.
Understanding how hospitals are offering chemotherapy infusions
Dr Jess Morgan at Leeds Children’s Hospital and Dr Gemma Bryan at University of Surrey hope to understand more about how hospitals are offering chemotherapy that needs to be given as infusions over a number of days.
How do DNA cutting errors lead to relapsed childhood leukaemia
Looking at how a process called 'cut-and-run' leads to genetic errors, and how those errors could be prevented in order to prevent relapse in childhood leukaemia.
A living review of new treatments for children and young people with relapsed and refractory rhabdomyosarcoma
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
Identifying the genetic changes in T-cell acute lymphoblastic leukaemia that fails to respond to chemotherapy
Deciphering the genomic landscape of childhood refractory t-cell acute lymphoblastic leukaemia
A novel laboratory model for neuroblastoma research
Establishment of an in vitro model of neuroblastoma initiation using pluripotent stem cell differentiation
Next generation molecular profiling of malignant rhabdoid tumours
Identifying which are the cellular molecules that drive growth and spread of rhabdoid tumours, and to use this information to nominate new treatment strategies and develop real-time diagnostic tests for personalising treatment
Understanding the biology of malignant rhabdoid tumours to develop targeted treatments
Improved therapeutic targeting in malignant rhabdoid tumours using discovery proteomics analysis